{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T07:19:26Z","timestamp":1771658366905,"version":"3.50.1"},"reference-count":52,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1016\/j.jacl.2008.02.004","type":"journal-article","created":{"date-parts":[[2008,2,25]],"date-time":"2008-02-25T22:25:41Z","timestamp":1203978341000},"page":"79-90","source":"Crossref","is-referenced-by-count":34,"title":["Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80 mg monotherapy: the SEACOAST II (high-dose) study"],"prefix":"10.1016","volume":"2","author":[{"given":"Christie M.","family":"Ballantyne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael H.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James M.","family":"McKenney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence H.","family":"Keller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiva R.","family":"Bajorunas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard H.","family":"Karas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2008.02.004_bib1","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1161\/CIRCULATIONAHA.106.179918","article-title":"Heart disease and stroke statistics\u20142007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee","volume":"115","author":"Rosamond","year":"2007","journal-title":"Circulation"},{"issue":"suppl 2","key":"10.1016\/j.jacl.2008.02.004_bib2","first-page":"51S","article-title":"Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults\u2014the evidence report","volume":"6","year":"1998","journal-title":"Obes Res"},{"key":"10.1016\/j.jacl.2008.02.004_bib3","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.clinthera.2007.05.002","article-title":"Hypertriglyceridemia and cardiovascular risk reduction","volume":"29","author":"Jacobson","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.jacl.2008.02.004_bib4","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2008.02.004_bib5","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.amjcard.2006.06.059","article-title":"Emerging strategies for increasing high-density lipoprotein","volume":"98","author":"Forrester","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2008.02.004_bib6","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2008.02.004_bib7","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2008.02.004_bib8","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1001\/jama.294.3.326","article-title":"Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women","volume":"294","author":"Ridker","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2008.02.004_bib9","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1001\/archinte.161.11.1413","article-title":"Non-high-density lipoprotein cholesterol level as predictor of cardiovascular disease mortality","volume":"161","author":"Cui","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacl.2008.02.004_bib10","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1161\/01.CIR.0000038496.57570.06","article-title":"Non-high-density lipoprotein cholesterol levels predict five-year outcome in the bypass angioplasty revascularization investigation (BARI)","volume":"106","author":"Bittner","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2008.02.004_bib11","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/MOL.0b013e32800ff750","article-title":"Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials","volume":"17","author":"Brown","year":"2007","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacl.2008.02.004_bib12","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2008.02.004_bib13","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1001\/jama.285.12.1585","article-title":"Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial","volume":"285","author":"Robins","year":"2001","journal-title":"JAMA"},{"issue":"suppl M","key":"10.1016\/j.jacl.2008.02.004_bib14","first-page":"MB8","article-title":"The emergence of triglycerides as a significant independent risk factor in coronary artery disease","volume":"19","author":"Assmann","year":"1998","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2008.02.004_bib15","doi-asserted-by":"crossref","first-page":"7B","DOI":"10.1016\/S0002-9149(98)00031-9","article-title":"Hypertriglyceridemia as a cardiovascular risk factor","volume":"81","author":"Austin","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2008.02.004_bib16","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1001\/jama.298.7.776","article-title":"Clinical utility of different lipid measures for prediction of coronary heart disease in men and women","volume":"298","author":"Ingelsson","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2008.02.004_bib17","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1001\/jama.298.7.786","article-title":"High-density lipoprotein as a therapeutic target: a systematic review","volume":"298","author":"Singh","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2008.02.004_bib18","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2337\/dc07-9917","article-title":"Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association","volume":"30","author":"Buse","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacl.2008.02.004_bib19","doi-asserted-by":"crossref","first-page":"26B","DOI":"10.1016\/S0002-9149(98)00034-4","article-title":"Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy","volume":"81","author":"Frost","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2008.02.004_bib20","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0002-9149(02)02436-0","article-title":"The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations","volume":"90","author":"Sacks","year":"2002","journal-title":"Am J Cardiol"},{"issue":"suppl 6","key":"10.1016\/j.jacl.2008.02.004_bib21","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1185\/030079905X59094","article-title":"Beyond statin therapy: why we need new thinking","volume":"21","author":"Assmann","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jacl.2008.02.004_bib22","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1161\/CIRCULATIONAHA.105.169180","article-title":"Managing abnormal blood lipids: a collaborative approach","volume":"112","author":"Fletcher","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2008.02.004_bib23","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1185\/030079905X43677","article-title":"Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel","volume":"21","author":"Shepherd","year":"2005","journal-title":"Curr Med Res Opin"},{"issue":"suppl 1","key":"10.1016\/j.jacl.2008.02.004_bib24","first-page":"S4","article-title":"Standards of medical care in diabetes\u20132006","volume":"29","year":"2006","journal-title":"Diabetes Care"},{"issue":"suppl 1","key":"10.1016\/j.jacl.2008.02.004_bib25","first-page":"S4","article-title":"Standards of medical care in diabetes\u20132007","volume":"30","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacl.2008.02.004_bib26","first-page":"549","article-title":"Effect of niacin on lipoproteins and atherosclerosis","volume":"1","author":"Ganji","year":"2006","journal-title":"Future Med"},{"key":"10.1016\/j.jacl.2008.02.004_bib27","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.2165\/00003495-200565180-00014","article-title":"Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia","volume":"65","author":"McCormack","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.jacl.2008.02.004_bib28","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/j.1368-5031.2004.00233.x","article-title":"Niaspan, the prolonged release preparation of nicotinic acid (niacin), the broad-spectrum lipid drug","volume":"58","author":"Carlson","year":"2004","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jacl.2008.02.004_bib29","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2008.02.004_bib30","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2008.02.004_bib31","first-page":"436","article-title":"Improving medication compliance: a review of selected issues","volume":"13","author":"Sclar","year":"1991","journal-title":"Clin Ther"},{"key":"10.1016\/j.jacl.2008.02.004_bib32","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0149-2918(01)80109-0","article-title":"A systematic review of the associations between dose regimens and medication compliance","volume":"23","author":"Claxton","year":"2001","journal-title":"Clin Ther"},{"key":"10.1016\/j.jacl.2008.02.004_bib33","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1016\/S0149-2918(03)80222-9","article-title":"The impact of reducing dose frequency on health outcomes","volume":"25","author":"Richter","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.jacl.2008.02.004_bib34","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1093\/eurheartj\/ehi841","article-title":"Benefits, challenges, and registerability of the polypill","volume":"27","author":"Sleight","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2008.02.004_bib35","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.amjcard.2005.04.019","article-title":"Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations","volume":"96","author":"Davidson","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2008.02.004_bib36","unstructured":"Ballantyne CM, Davidson MH, McKenney JM, Keller LH, Bajorunas DR, Karas RH. Comparison of the safety and efficacy of a combination tablet of niacin extended-release and simvastatin with simvastatin monotherapy: the SEACOAST I study. Am J Cardiol. In press."},{"key":"10.1016\/j.jacl.2008.02.004_bib37","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/clinchem\/20.4.470","article-title":"Enzymatic determination of total serum cholesterol","volume":"20","author":"Allain","year":"1974","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacl.2008.02.004_bib38","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1093\/clinchem\/47.4.712","article-title":"Optimization of \u03b2-quantification methods for high-throughput applications","volume":"47","author":"Cole","year":"2001","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacl.2008.02.004_bib39","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low density lipoprotein cholesterol in plasma without the use of the ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacl.2008.02.004_bib40","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/clinchem\/32.1.63","article-title":"Direct enzymic measurement of glycerides in serum and in lipoprotein fractions","volume":"32","author":"Kohlmeier","year":"1986","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacl.2008.02.004_bib41","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/clinchem\/28.6.1379","article-title":"Dextran sulfate-Mg++ precipitation procedure for quantification of high density lipoprotein cholesterol","volume":"28","author":"Warnick","year":"1982","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacl.2008.02.004_bib42","unstructured":"Product Insert. Autokit Apo A-1: Code no. 991-27201. Rev. #1\/9603IBD002K. Wako Pure Chemical Industries, Ltd., Osaka, Japan."},{"key":"10.1016\/j.jacl.2008.02.004_bib43","unstructured":"Product Insert. Autokit Apo B: Code no. 993-27401. Rev. #1\/9603IBD002K. Wako Pure Chemical Industries, Ltd., Osaka, Japan."},{"key":"10.1016\/j.jacl.2008.02.004_bib44","unstructured":"Product Insert. Autokit Lp(a): Code no. 995-41901. Rev. #1\/9903IBD00K. Wako Pure Chemical Industries, Ltd., Osaka, Japan."},{"key":"10.1016\/j.jacl.2008.02.004_bib45","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11883-005-0072-7","article-title":"Rationale for combination therapy with statin drugs in the treatment of dyslipidemia","volume":"7","author":"Ansell","year":"2005","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.jacl.2008.02.004_bib46","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1368-5031.2004.00289.x","article-title":"Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia","volume":"58","author":"Davidson","year":"2004","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jacl.2008.02.004_bib47","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.amjcard.2004.10.012","article-title":"Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial)","volume":"95","author":"Grundy","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2008.02.004_bib48","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.clinthera.2007.07.018","article-title":"Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g\/d to simvastatin 40 mg\/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study","volume":"29","author":"Davidson","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.jacl.2008.02.004_bib49","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2008.02.004_bib50","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1161\/01.CIR.0000148955.19792.8D","article-title":"Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins","volume":"110","author":"Taylor","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2008.02.004_bib51","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1185\/030079906X148508","article-title":"The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3","volume":"22","author":"Taylor","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jacl.2008.02.004_bib52","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0002-9149(03)00007-9","article-title":"Comparison of once-daily, niacin extended-release\/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE])","volume":"91","author":"Bays","year":"2003","journal-title":"Am J Cardiol"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287408000718?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287408000718?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,2]],"date-time":"2020-05-02T07:45:35Z","timestamp":1588405535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287408000718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["S1933287408000718"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2008.02.004","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2008,4]]}}}